Hematologic parameters before therapy and grades 3-4 toxicity during therapy
| Toxicity grade at baseline . | Neutropenia . | Anemia . | Thrombocytopenia . | |||
|---|---|---|---|---|---|---|
| No. of patients at baseline . | Grade 3-4 during therapy, n . | No. of patients at baseline . | Grade 3-4 during therapy . | No. of patients at baseline . | Grade 3-4 during therapy, n . | |
| Thalidomide | ||||||
| 0 | 39 | 4 | 22 | 1* | ||
| 1 | 0 | 14 | 1* | 9 | ||
| 2 | 5 | 21 | 1 | 4 | ||
| 3 | 0 | 5 | 6 | |||
| 4 | 0 | 0 | 3 | |||
| Overall | 44 | 44 | 44 | |||
| Lenalidomide | ||||||
| 0 | 39 | 7 | 6 | 28 | 5 | |
| 1 | 0 | 16 | 1* | 7 | 3 | |
| 2 | 1 | 1* | 17 | 3 | 1 | |
| 3 | 1 | 1* | 2 | 3 | 2* | |
| 4 | 0 | 0 | 0 | |||
| Overall | 41 | 41 | 41 | |||
| Lenalidomide plus prednisone | ||||||
| 0 | 35 | 18 | 4 | 28 | 1* | |
| 1 | 2 | 1 | 14 | 7 | 4 | |
| 2 | 0 | 21 | 6 | 3 | ||
| 3 | 1 | 1 | 1 | 1* | ||
| 4 | 2 | 0 | 4 | |||
| Overall | 40 | 40 | 40 | |||
| P | .001 | .001 | .001 | |||
| Toxicity grade at baseline . | Neutropenia . | Anemia . | Thrombocytopenia . | |||
|---|---|---|---|---|---|---|
| No. of patients at baseline . | Grade 3-4 during therapy, n . | No. of patients at baseline . | Grade 3-4 during therapy . | No. of patients at baseline . | Grade 3-4 during therapy, n . | |
| Thalidomide | ||||||
| 0 | 39 | 4 | 22 | 1* | ||
| 1 | 0 | 14 | 1* | 9 | ||
| 2 | 5 | 21 | 1 | 4 | ||
| 3 | 0 | 5 | 6 | |||
| 4 | 0 | 0 | 3 | |||
| Overall | 44 | 44 | 44 | |||
| Lenalidomide | ||||||
| 0 | 39 | 7 | 6 | 28 | 5 | |
| 1 | 0 | 16 | 1* | 7 | 3 | |
| 2 | 1 | 1* | 17 | 3 | 1 | |
| 3 | 1 | 1* | 2 | 3 | 2* | |
| 4 | 0 | 0 | 0 | |||
| Overall | 41 | 41 | 41 | |||
| Lenalidomide plus prednisone | ||||||
| 0 | 35 | 18 | 4 | 28 | 1* | |
| 1 | 2 | 1 | 14 | 7 | 4 | |
| 2 | 0 | 21 | 6 | 3 | ||
| 3 | 1 | 1 | 1 | 1* | ||
| 4 | 2 | 0 | 4 | |||
| Overall | 40 | 40 | 40 | |||
| P | .001 | .001 | .001 | |||
Grade 4 only.